Soleno Therapeutics
Presence
Soleno Therapeutics is a company listed under the stock ticker SLNO (US).
Executives
View the org chart displaying its 16 main executives
Most searched biographies at Soleno Therapeutics
- Anish Bhatnagar, Chief Executive Officer and Director
- William Harris, Director
- Birgitte Volck, Director
Popular executive movements at Soleno Therapeutics
- Meredith Manning has joined the company as Chief Commercial Officer (posted on January 25 2024).
- Dairine Dempsey has joined the company as Vice President, Europe (posted on January 25 2024).
- Lauren Budesheim has joined the company as Vice President of Human Resources (posted on January 25 2024).
Click here to view some more movements at Soleno Therapeutics
Create your alert
to follow the executive moves at Soleno Therapeutics.
Biotechnology
Soleno Therapeutics has 2,285 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Karius has just announced a $100 Million fundraising (posted on May 3 2024).
- Transcarent has just announced a $126 Million fundraising (posted on May 2 2024).
- WindRose Health Investors has announced the acquisition of SubjectWell (posted on May 2 2024).
Popular contacts in Biotechnology
News
Press releases by Soleno Therapeutics
- Soleno Therapeutics Announces Updated Top-line Results from Phase III Trial of DCCR for Treatment of Prader-Willi Syndrome – Soleno Therapeutics Inc.
- Soleno Therapeutics to Participate in Fireside Chat at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit – Soleno Therapeutics Inc.
- Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2020 Financial Results – Soleno Therapeutics Inc.
- Soleno Therapeutics Added to Russell 3000® Index – Soleno Therapeutics Inc.
- Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2020 Financial Results – Soleno Therapeutics Inc.
- Soleno Therapeutics Announces Closing of $57.5 Million Public Offering of Common Stock, Including the Full Exercise of Underwriters’ Option to Purchase Additional Shares – Soleno Therapeutics Inc.
- Soleno Therapeutics Added to Russell 3000® Index – Soleno Therapeutics Inc.
- Soleno Therapeutics Announces Closing of $57.5 Million Public Offering of Common Stock, Including the Full Exercise of Underwriters’ Option to Purchase Additional Shares – Soleno Therapeutics Inc.
- Soleno Therapeutics Announces Pricing of $50 Million Public Offering of Common Stock – Soleno Therapeutics Inc.
- Soleno Therapeutics Announces Proposed Public Offering of Common Stock – Soleno Therapeutics Inc.
- View more press releases Close
Social media about Soleno Therapeutics
- Soleno Therapeutics on Wikipedia, Google News & Yahoo Finance
- Soleno Therapeutics on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Anish Bhatnagar 
Call Soleno Therapeutics at +1 650...
